With molecular improvements in several agents targeting components of pathways and processes crucial to neoplastic transformation and progression, molecular-targeted therapy for GISTs has become possible. Thus, because of the malignant potential of GISTs and the availability of improved treatments, it is important to distinguish GISTs from other GIMTs.
The first objective of this retrospective study was to reclassify colorectal mesenchymal tumors, from files collected over 20 years, to determine if, based on immunohistologic features, the lesions were truly GISTs. The second objective was to identify the relationship between clinicopathologic features and prognostic factors of GISTs in the colon and rectum.
Methods

Case histories and follow-up
Cases of mesenchymal tumor involving the colorectum (coded as LM, LMS, or stromal tumor) were retrieved from the database of the Department of Surgical Pathology at Taichung Veterans General Hospital for the period 1 January 1983 to 31 December 2001. A total of 27 cases were procured and reviewed. Excluded from the study were 1 case of perirectal LM that resembled uterine LM and 1 case of serosal fibromyoma.
For all patients, clinical data (age and gender), tumor characteristics (location, gross appearance [polypoid or intramural], size [maximal diameter in centimeters]), surgical procedures, and survival outcomes, were retrospectively obtained from hospital records and, where possible, confirmed by telephone.
Histologic evaluation
All hematoxylin and eosin-stained slides for each case were reviewed. The following features were recorded in all cases: predominant cell type, cellularity, mitotic count per 10 high-power fields (hpfs), and tumor hemorrhage and necrosis (unrelated to mucosal ulceration). The definition of predominant cell type depended on the percentage of epithelioid tumor cells present: the presence of more than 50% epithelioid cells was defined as epithelioid cell type; 10-50% as mixed; and less than 10% as spindle cell type. Low cellularity indicated that tumor cells had ample cytoplasm separating the nuclei. Mitosis was counted in the most cellular and mitotically active areas for 10 hpfs. Tumor necrosis and hemorrhage that could easily be seen under low-power microscopy (40×) was defined as macroscopic. Nuclear pleomorphism that could be seen under middle-power microscopy (100×) was defined as high grade, and under high-power microscopy as low grade.
Immunohistochemistry
The following antibodies were applied to antigens from a representative sample from each patient: CD117 (DAKO, Copenhagen, Denmark; polyclonal, dilution 1:300), CD34 (DAKO; monoclonal, dilution 1:50), smooth muscle actin (DAKO; actin M851, monoclonal, dilution 1:100), desmin (DAKO; monoclonal, dilution 1:100), neuron-specific enolase (NSE) (DAKO; monoclonal, dilution 1:200), and S-100 protein (DAKO; polyclonal, dilution 1:400).
Microwave-based epitope retrieval agent (320 mg sodium EDTA/L, pH 8.0) was applied before immunostaining for CD34 and CD117. Immunostaining was performed using the avidin biotin peroxidase complex detection system with diaminobenzidine as the chromogen. The staining was interpreted only when internal positive controls were present (mast cells for CD117, endothelial cells for CD34, smooth muscle cells for actin M851, and nerve bundles for NSE and S-100 protein); however, this rule was not used with desmin because normal muscle tissue was sometimes absent in the slides. Four semi-quantifiable scores were used, based on the percentage of positive tumor cells (0-25%, 1+; 25-50%, 2+; 50-75%, 3+; and 75-100%, 4+). Two of the authors evaluated the results, and consensus was achieved in each case.
Statistical analysis
The relationship between KIT expression and clinicopathologic features (especially local recurrence, distant metastasis and lethality) was investigated by Pearson's Chi-squared test, Fisher's exact test, independent t test, and Mann-Whitney U test (SPSS for Windows, version 10.1; SPSS Inc, Chicago, IL, USA). Survival analysis was performed by log-rank test. A p value of less than 0.05 was considered statistically significant. Univariate and multivariate analyses were applied to all data.
Results
Clinical features
The clinical characteristics of the 25 patients are summarized in Table 1 . There were 16 males (64%) and 9 females (36%), and patient age ranged from 37-79 years (mean, 59.0 ± 10.7 years). Eighteen patients had the following symptoms: constipation (n = 6); palpable mass (6); anal bleeding (3); bloody stools (2); Prognosis of colorectal mesenchymal tumors diarrhea (2); tenesmus (2); and tarry stools (1) . The most common tumor location was the rectum (n = 20), followed by the colon (5). The mean tumor maximum diameter was 3.98 ± 3.96 cm (range, 0.2-12.0 cm). Grossly, the tumors presented as submucosal polyps (n = 7) or intramural tumors (18). They were described as having the following consistency: graybrown soft (n = 8); gray-tan-brown firm (8) ; gray soft (6); yellow-tan-white firm (2), or yellow-brown soft (1) . Focal hemorrhage (n = 3), cystic changes (1) and necrosis (1) were noted on sectioning.
Treatment and follow-up
Polypoid tumors (n = 7) were typically treated with polypectomy. The smallest intramural tumors (≤ 2 cm in diameter) were treated with per-anal excision (n = 5), although enucleation is the traditional treatment. Of intramural tumors that were larger than 2 cm but not more than 5 cm in diameter, 4 were treated with per-anal excision, while segmental resection was performed in 2 cases. Intramural tumors larger than 5 cm in diameter were commonly treated with segmental resection (n = 6), whereas per-anal excision was performed in only 1 case. No patient received postoperative radiotherapy and/or chemotherapy.
The mean follow-up period was 40.6 ± 38.1 months (range, 0-158 months). Local recurrence (n = 6) occurred in 4 patients treated with per-anal excision, and in 2 treated with segmental resection. In the latter group, 1 patient had local recurrence and liver metastasis 23 months after segmental resection. He subsequently died from his disease without being treated with imatinib mesylate (STI571; Gleevec TM ; Novartis Pharmaceuticals Corp, East Hanover, NJ, USA). Another patient who had local recurrence 48.5 months after segmental resection also died from his disease. Thus, survival analysis revealed that 2 patients died from colorectal mesenchymal cancer; 3 died from other diseases (chronic renal failure, cervical cancer, intracranial hemorrhage); 2 patients with local recurrence after per-anal excision were alive with disease; and 18 were alive without disease. AWD = alive with disease; AWOD = alive without disease; DFD = died from disease; DFOD = died from other disease; I = intramural; P = polypoid; PAE = per-anal excision; PP = polypectomy; SR = segmental resection.
Microscopic findings
Histopathologic characteristics are summarized in Table 2 . A spindle-cell pattern was seen in most cases (92%); 2 tumors had mixed spindle and epithelioid cytology. Over half of all tumors (64%) had high cellularity. Mean mitotic count was 2.88 ± 5.04 per hpfs (range, 0-15 per 10 hpfs). Mitotic count was 1-5 per 10 hpfs in 5 cases (20%); these tumors were originally diagnosed as LM, smooth muscle tumor (SMT), STUMP and GISTs (committed and combined type). In another 5 cases (20%), mitotic count was more than 5 per 10 hpfs; these tumors were originally diagnosed as LM, LMS and GIST (neural type).
Nuclear atypia was present in 6 tumors (24%): 4 as high-grade and 2 as low-grade. Six tumors (24%) showed hemorrhage on sectioning, 3 of which were microscopic foci. Coagulation necrosis was seen in 5 cases (20%): it was macroscopic in 3 cases and microscopic in 2. Most of the cases with hemorrhage and necrosis represented large and mitotically active tumors.
Histologic examination of tumor extension into the peripheral surgical margin was observed in 4 of 10 peranal excision specimens, and 2 of 8 segmental excision specimens. Skeinoid fibers and focal calcification were not seen in all cases. No lymph node metastasis was detected in 6 patients treated with segmental resection (average of 5 nodes studied from each).
Immunohistochemical findings
Immunohistochemical findings are summarized in Table 2 . CD117 (KIT)-immunoreactivity was identified in 18 of 25 cases (72%) by diffuse membrane and cytoplasmic staining in ≥ 50% of tumor cells. CD34-positivity was seen in all these cases, with only 1 case having ≤ 25% of tumor cells positive. An immunonegative result for both actin M851 and desmin was documented in 2 tumors, and for both NSE and S-100 in 1 tumor. Immunohistochemistry showed negative CD117 staining for 7 polypoid tumors, which were immunopositive for actin M851 and desmin, but immunonegative for CD34, NSE, and S-100 protein. No  3+  4+  0  0  3+  1+  18  Mixed  High  1  No  MI  MA  3+  1+  2+  1+  1+  1+  19  Spindle  High  1  No  No  No  3+  4+  1+  1+  0  1+  20  Spindle  High  0  No  No  No  4+  4+  1+  1+  2+  2+  21  Spindle  High  14  High  MA  MA  2+  4+  0  0  2+  1+  22  Spindle  High  15  High  MA  MA  4+  4+  4+  0  4+  2+  23  Spindle  High  13  Low  MI  MI  4+  4+  1+  0  4+  2+  24  Spindle  High  11  High  MI  MI  4+  4+  3+  1+  1+  1+  25  Spindle  Low  0  No  No  No  4+  4+  1+  1+  2+  1+ *Scores are based on the percentage of positive tumor cells: 1+ = 0-25%; 2+ = 25-50%; 3+ = 50-75%; 4+ = 75-100%. hpf = high-power field; MA = macroscopic; MI = microscopic; Mixed = mixed spindle and epithelial; NSE = neuron-specific enolase.
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Statistical evaluation
The relationship between KIT expression and clinicopathologic features is summarized in Table 3 .
The following variables were significantly associated with different CD117 results from Fisher's exact test: symptomatic presentation (p = 0.007); tumor location (p < 0.001); gross features (p < 0.001); cellularity (p < 0.001); and type of surgery (p < 0.001). In addition, significant relationships were identified by the Mann-Whitney U test between CD117 status and tumor size (p < 0.001), and between CD117 status and mitotic count (p = 0.034). Seven patients had CD117-negative tumors: all except 2 (1 with tarry stools and diarrhea, 1 with bloody stools) were asymptomatic (71.4%). Tumors showed polypoid gross features (100%), small size (0.50 ± 0.10 cm), low cellularity (100%), and a 0 mitotic count per 10 hpfs (100%). After polypectomy, no malignant behavior (local recurrence, distant metastasis, lethality) occurred during follow-up (35.9 ± 21.6 months). 
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Most of our cases (n = 18) were diagnosed as GISTs based on combined histopathologic evaluation and immunohistochemical findings through identification of the CD117 marker. By univariate analysis (Pearson's Chi-squared test), the following clinicopathologic variables were significantly associated with increased lethality: tumor size (p = 0.049); mitotic count (p = 0.019); nuclear atypia (p = 0.019); and tumor necrosis (p = 0.045). In the survival analysis, a significant result was obtained for mitotic activity (cut-off value, 10 mitoses per 10 hpfs) (p = 0.0304; log-rank test). Using Pearson's Chi-squared test, nuclear atypia was associated, but not significantly, with increased local recurrence (p = 0.087); tumor necrosis (p = 0.071) and hemorrhage (p = 0.071) were associated, but not significantly, with increased metastasis. No appropriate interpretation of results could be obtained from multivariate analysis.
Discussion
Most gastrointestinal mesenchymal neoplasms, previously classified as LMs, schwannomas, leiomyoblastomas, or LMSs, are today classified as GISTs based on molecular and immunohistologic features. 5 GISTs with a c-kit proto-oncogene mutation are characterized by over-expression of the KIT protein, a transmembrane tyrosine kinase receptor for stemcell factors.
By histopathologic evaluation and CD117 positivity, 2 clinicopathologically different categories could be identified from our colorectal mesenchymal tumors. The 7 CD117-negative cases (1 had originally been diagnosed as GIST, and 6 as LM) were gross intraluminal polyps, and were less symptomatic than the CD117-positive cases. They had smaller average size (0.5 cm), lower mitotic count and cellularity than the CD117-positive cases, and showed only smooth muscle differentiation immunohistochemically. After polypectomy, no malignant behavior (local recurrence, distant metastasis, lethality) was found in these cases. Similar cases in the study of Miettinen et al 6 were regarded as submucosal LMs arising from the muscularis mucosae.
The 18 CD117-positive cases in our study (3 tumors had originally been diagnosed as LMS, 1 as SMT, 1 as STUMP, 9 as LM, and 4 as GIST) were gross intramural masses, and were frequently symptomatic. Compared with the CD117-negative cases, they were located in the rectum, and had larger tumor size, higher cellularity, higher mitotic count, and necrosis and hemorrhage, and showed diverse smooth muscle and neural differentiation immunohistochemically. They were treated with peranal excision or segmental resection, and 6 of them had malignant behavior (recurrence, metastasis, lethality). They were regarded as true GISTs, originating from Cajal cells around the myenteric plexus in the muscularis propria.
In another study by Miettinen et al, 7 most rectal stromal tumors were GISTs, which had a spectrum ranging from minimal indolent tumors to overt sarcomas. Furthermore, LMs of the muscularis mucosae were more common than GISTs in the colon, but as common as, or less frequent than, GISTs in the rectum. 8, 9 These findings were similar to those in our study.
However, some tumors have typical clinicopathologic and cytogenetic features of GIST, but do not express detectable KIT protein. 10 Recently, a subset of GISTs was found to have platelet-derived growth factor receptor (PDGFR) α gene mutation rather than c-kit receptor tyrosine kinase (KIT) mutation. 11, 12 Thus, for now, GISTs have proved to have KIT or PDGFR α mutations. The PDGFR α gene and KIT gene are adjacent on human chromosome 4, and there is high amino-acid similarity between them. 11 West et al 13 generated an antiserum against 1 GIST-specific gene, which was named "discovered on GIST 1" (DOG1). It encodes for the hypothetical protein FLJ10261. DOG1 is highly expressed, not only in typical GISTs, but also in KIT-mutationnegative GISTs.
In our 18 cases of GIST, both the univariate and survival analyses revealed that mitotic count was a statistically significant predictor of lethality. Indeed, a high mitotic count has generally been accepted as the best indicator of malignancy in GIST. 14, 15 In the study by Rodolico et al, 16 a cut-off point of 5 mitoses per 10 hpfs appeared to show a significant level of discrimination between benign and malignant clinical behavior. In addition, Emile et al 17 mentioned that mitotic activity was the only independent predictive factor of metastases identified in multivariate analysis (p < 0.001).
Tumor size, tumor necrosis and nuclear atypia were also significant predictors of lethality in the univariate, but not in the survival, analysis in our study. In other studies, tumor size and mitotic count were the most reliable predictors of outcome, 9 and most rectal GISTs larger than 5 cm in size, or with more than 5 mitoses per 50 hpfs, behaved aggressively. 8 In the latter study, tumor necrosis and nuclear atypia were seen in 40 cases (30%), most of which were large and mitotically active tumors. 8 Large tumor size and Prognosis of colorectal mesenchymal tumors high mitotic count are common findings in highgrade gastrointestinal sarcoma and suggest a poor prognosis. Rodolico et al 16 showed that neural phenotype was associated with a tendency towards slightly improved survival. However, our results indicated no significant influence on survival after GIST differentiation to nerve or smooth muscle. Moreover, because the p16 locus is consistently involved in chromosomal losses found in malignant GISTs, p16 immunohistochemical assessment seems a promising method for determining GIST prognosis. 18 Snare polypectomy is an adequate treatment for submucosal LM, but complete tumor removal and follow-up are necessary for any tumors with atypia or mitotic activity. 6 The rarity of colorectal GISTs, and a scarcity of patients undergoing long-term follow-up, make it difficult to determine the proper extent of surgical resection for this disease. The most highly recommended approach has been complete (abdominoperineal or segmental) resection to avoid tumor rupture and prevent the high frequency of local recurrence after local excision. In Walsh and Mann's series 19 of 18 intramuscular anorectal GISTs, 6 of 10 tumors treated with local excision recurred, whereas 0 of 8 tumors treated with abdominoperineal resection recurred. Thus, the authors pointed out the failure of local excision to control local spread.
In our study, 4 of 10 per-anal excision cases recurred, and 2 of 8 segmental resection cases also showed local recurrence and lethality; thus, no significant difference existed between the mode of operation and prognosis. Because the latter 2 cases of segmental resection were high-risk GISTs (> 10 cm in size; mitotic count > 10 per 10 hpfs), surgical treatment alone was probably inadequate for disease control. The segmental resections in our study may also have been incomplete. A prospective clinical trial may be needed to further define the appropriate treatment for GISTs.
Mutant isoforms of the KIT or PDGF receptors expressed by GISTs are considered the therapeutic targets for imatinib, which is a specific inhibitor of such tyrosine kinase receptors. 20 Phase I-III clinical trials demonstrated the efficacy of imatinib in the treatment of metastatic GISTs, 21 and it is possible that the adjuvant and neoadjuvant use of imatinib in the overall management of advanced GISTs may facilitate surgeons' success. 22 Hiramatsu et al 23 reported the case of a patient with huge gastric GIST who underwent effective neoadjuvant therapy with imatinib followed by surgical resection.
In conclusion, 2 clinicopathologically different categories, intramural GISTs and polypoid submucosal LMs, could be identified from our colorectal mesenchymal tumors; however, future molecular genetic studies are recommended to prove a lack of PDGFR α or KIT gene mutation in these polypoid submucosal LMs. Our study suggests that, because of malignant potential, GIST is a better categorization than SMT. Prognosis is strictly related to the number of mitoses. Larger patient numbers are needed to evaluate the prognostic significance of tumor size, nuclear atypia and tumor necrosis. At present, surgery is the standard treatment for primary operable GISTs, and radical surgical removal provides the only chance for long-term survival. 22 Although molecular-targeted therapy (imatinib) has demonstrated efficacy in the treatment of unresectable and metastatic GISTs, some studies have shown that GISTs can develop resistance to imatinib; 24 thus, additional therapeutic strategies are needed.
